

RECEIVED
CENTRAL FAX CENTER
MAR 12 2007

AMENDMENTS TO THE CLAIMS

1-4. (Cancelled)

5. (Previously presented) A composition formulated for topical administration, said composition comprising as the sole active ingredients a tricyclic antidepressant and a corticosteroid in amounts that, when administered together to a patient having an immunoinflammatory disorder, inhibit or reduce inflammation or otherwise treat said disorder, wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, imipramine, trimipramine, nortriptyline, and protriptyline.

6. (Original) The composition of claim 5, wherein said corticosteroid is in a low dose.

7. (Original) A composition formulated for inhalation administration, said composition comprising a tricyclic antidepressant and a corticosteroid in amounts that, when administered together to a patient having an immunoinflammatory disorder, inhibit or reduce inflammation or otherwise treat said disorder.

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

8. (Original) The composition of claim 7, wherein said corticosteroid is in a low dose.

9. (Original) A method for treating an immunoinflammatory disorder in patient in need thereof, said method comprising administering to said patient a tricyclic antidepressant and a low dose corticosteroid, wherein the tricyclic antidepressant and the corticosteroid are administered simultaneously, or within 14 days of each other, in amounts that together are sufficient to treat said disorder.

10. (Original) The method of claim 9, wherein said tricyclic antidepressant is administered topically.

11. (Original) The method of claim 9, wherein said immunoinflammatory disorder is selected from the group consisting of rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, stroke-induced brain cell death, ankylosing spondylitis, fibromyalgia, asthma, multiple sclerosis, type I diabetes, systemic lupus erythematosus, scleroderma, systemic sclerosis, and Sjögren's syndrome.

12. (Original) The method of claim 9, wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-

hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, doxepin, imipramine, trimipramine, nortriptyline, amitriptyline, and protriptyline.

13. (Original) The method of claim 9, wherein said tricyclic antidepressant and said corticosteroid are administered simultaneously.

14. (Original) A method for treating an immunoinflammatory disorder selected from psoriasis, ulcerative colitis, Crohn's disease, stroke-induced brain cell death, ankylosing spondylitis, fibromyalgia, asthma, multiple sclerosis, type I diabetes, systemic lupus erythematosus, scleroderma, systemic sclerosis, and Sjögren's syndrome in a patient in need thereof, said method comprising administering to said patient a tricyclic antidepressant and a corticosteroid, wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, amitriptyline, desipramine, clomipramine, doxepin, imipramine, trimipramine, nortriptyline, and protriptyline; wherein the tricyclic antidepressant and the corticosteroid are administered simultaneously, or within 14 days of each other, in amounts that together are sufficient to treat said disorder.

15. (Original) The method of claim 14, whercin said tricyclic antidepressant is administered topically.

16. (Original) The method of claim 14, wherein said tricyclic antidepressant and said corticostcroid are administered simultaneously.

17. (Original) A method for treating rheumatoid arthritis in a patient in need thereof, said method comprising administering to said patient a tricyclic antidepressant and a corticosteroid, wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, doxepin, imipramine, trimipramine, nortriptyline, and protriptyline; whercin the tricyclic antidepressant and the corticosteroid are administered simultaneously, or within 14 days of each other, in amounts that together are sufficient to treat said rheumatoid arthritis.

18. (Original) The method of claim 17, whercin said tricyclic antidepressant is administered topically.

19. (Original) The method of claim 17, wherein said tricyclic antidepressant and said corticosteroid are administered simultaneously.

20. (Original) A method for treating an immunoinflammatory disorder in patient in need thereof, said method comprising administering to said patient a tricyclic antidepressant selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, imipramine, trimipramine, nortriptyline, amitriptyline, and protriptyline, and a corticosteroid, wherein said tricyclic antidepressant and the corticosteroid are administered simultaneously or within 14 days of each other in amounts that together are sufficient to treat said disorder and said tricyclic antidepressant is topically administered to said patient.

21. (Original) The method of claim 20, wherein said immunoinflammatory disorder is selected from rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, stroke-induced brain cell death, ankylosing spondylitis, fibromyalgia, asthma, multiple sclerosis, type I diabetes, systemic lupus erythematosus, scleroderma, systemic sclerosis, and Sjögren's syndrome.

22. (Original) The method of claim 20, wherein said corticosteroid is topically administered to said patient.

23. (Original) The method of claim 20, wherein said corticosteroid is systemically administered to said patient.

24. (Original) The method of claim 20, wherein the corticosteroid is administered at a low dose.

25. (Original) The method of claim 20, wherein said tricyclic antidepressant and said corticosteroid are administered simultaneously.

26. (Original) A method for treating an immunoinflammatory disorder selected from rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, stroke-induced brain cell death, ankylosing spondylitis, fibromyalgia, asthma, multiple sclerosis, type I diabetes, systemic lupus erythematosus, scleroderma, systemic sclerosis, and Sjögren's syndrome, said method comprising administering to a patient a tricyclic antidepressant and a corticosteroid, wherein said tricyclic antidepressant and the corticosteroid are administered simultaneously or within 14 days of each other in amounts that together are sufficient to treat said disorder and said tricyclic antidepressant is topically administered to said patient.

27. (Original) The method of claim 26, wherein said corticosteroid is topically administered to said patient.

28. (Original) The method of claim 26, wherein said corticosteroid is systemically administered to said patient.

29. (Original) The method of claim 26, wherein the corticosteroid is administered at a low dose.

30. (Original) The method of claim 26, wherein said tricyclic antidepressant and said corticosteroid are administered simultaneously.

31. (Original) A method for treating an immunoinflammatory disorder in a patient in need thereof, said method comprising administering to said patient a tricyclic antidepressant and a corticosteroid, wherein said tricyclic antidepressant and the corticosteroid are administered simultaneously or within 14 days of each other in amounts that together are sufficient to treat said disorder and said tricyclic antidepressant is administered by inhalation to said patient.

32. (Original) The method of claim 31, wherein said corticosteroid is administered by inhalation to said patient.

33. (Original) The method of claim 31, wherein the corticosteroid is administered at a low dose.

34. (Original) The method of claim 31, wherein said tricyclic antidepressant and said corticosteroid are administered simultaneously.

35. (Previously presented) A composition formulated for inhalation administration, said composition comprising a tricyclic antidepressant and a corticosteroid.

36. (Previously presented) The composition of claim 35, wherein said tricyclic antidepressant is nortriptyline.

37. (Previously presented) A composition formulated for oral administration, said composition comprising a tricyclic antidepressant and a corticosteroid.

38. (Previously presented) The composition of claim 37, wherein said tricyclic antidepressant is nortriptyline.

39. (Previously presented) A method for treating asthma in a patient in need thereof, said method comprising administering to said patient a composition comprising a tricyclic antidepressant and a corticosteroid, wherein said composition is formulated for inhalation administration.

40. (Previously presented) The method of claim 39, wherein said tricyclic antidepressant is nortriptyline.

41. (Previously presented) A method for treating asthma in a patient in need thereof, said method comprising administering to said patient a composition comprising a tricyclic antidepressant and a corticosteroid, wherein said composition is formulated for oral administration.

42. (Previously presented) The method of claim 41, wherein said tricyclic antidepressant is nortriptyline.

43. (Cancelled)

44. (Currently amended) A composition formulated for oral, rectal, intravenous, intramuscular, subcutaneous, inhalation, vaginal, or ophthalmic administration, said composition comprising a tricyclic antidepressant and a corticosteroid, wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, doxepin, imipramine, trimipramine, nortriptyline, amitriptyline, and protriptyline.

45. (Previously presented) The composition of claim 44, wherein said tricyclic antidepressant is present at a dosage between 1-600 mg.

46. (Previously presented) The composition of claim 45, wherein said tricyclic antidepressant is present at a dosage between 1-400 mg.

47. (Previously presented) The composition of claim 46, wherein said tricyclic antidepressant is present at a dosage between 1-300 mg.

48. (Currently amended) The composition of claim 44, wherein said corticosteroid is present at a dosage between 0.05-200 mg.

49. (Previously presented) The composition of claim 48, wherein said corticosteroid is present at a dosage between 0.1-60 mg.

50. (Previously presented) The composition of claim 49, wherein said corticosteroid is present at a dosage between 0.1-5 mg.

51. (Previously presented) The composition of claim 44, wherein said tricyclic antidepressant is present at a dosage equivalent to a dosage of amoxapine between 1-600 mg.

52. (Previously presented) The composition of claim 51, wherein said tricyclic antidepressant is present at a dosage equivalent to a dosage of amoxapine between 1-400 mg.

53. (Previously presented) The composition of claim 52, wherein said tricyclic antidepressant is present at a dosage equivalent to a dosage of amoxapine between 1-300 mg.

54. (Previously presented) The composition of claim 44, wherein said corticosteroid is present at a dosage equivalent to a dosage of prednisolone between 0.05-200 mg

55. (Previously presented) The composition of claim 54, wherein said corticosteroid is present at a dosage equivalent to a dosage of prednisolone between 0.1-60 mg.

56. (Previously presented) The composition of claim 55, wherein said corticosteroid is present at a dosage equivalent to a dosage of prednisolone between 0.1-5 mg.

57. (Currently amended) A composition formulated for oral, rectal, intravenous, intramuscular, subcutaneous, inhalation, vaginal, or ophthalmic administration, said composition comprising a tricyclic antidepressant and a corticosteroid,

wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, doxepin, imipramine, trimipramine, nortriptyline, amitriptyline, and protriptyline;

wherein said tricyclic antidepressant is present at a dosage between 1-300 mg; and

wherein said corticosteroid is present at a dosage between 0.1-60 mg.

58. (Previously presented) The composition of claim 57, wherein said corticosteroid is present at a dosage between 0.1-5 mg.

59. (Currently amended) A composition formulated for oral, rectal, intravenous, intramuscular, subcutaneous, inhalation, vaginal, or ophthalmic administration, said composition comprising a tricyclic antidepressant and a corticosteroid,

wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, doxepin, imipramine, trimipramine, nortriptyline, amitriptyline, and protriptyline;

wherein said tricyclic antidepressant is present at a dosage equivalent to a dosage of amoxapine between 1-300 mg; and

wherein said corticosteroid is present at a dosage equivalent to a dosage of prednisolone between 0.1-60 mg.

60. (Previously presented) The composition of claim 59, wherein said corticosteroid is present at a dosage equivalent to a dosage of prednisolone between 0.1-5 mg

61. (Previously presented) A composition formulated for topical administration, said composition comprising as the sole active ingredients a tricyclic antidepressant and a corticosteroid, wherein said tricyclic antidepressant is selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, imipramine, trimipramine, nortriptyline, and protriptyline.

62. (New) The composition of claim 38, wherein said corticosteroid is prednisolone.

63. (New) The composition of claim 62, wherein said tricyclic antidepressant is present at a dosage between 1-300 mg and said corticosteroid is present at a dosage between 0.1-60 mg.

64. (New) The composition of claim 63, wherein said corticosteroid is present at a dosage between 0.1-5 mg.